Public Release: 

Cultural and economic factors affect European antidepressant use

King's College London

Public attitudes towards mental illness and levels of healthcare spending may explain the huge variation in antidepressant use across Europe, according to a new study by researchers from the Institute of Psychiatry, Psychology & Neuroscience (IoPPN) at King's College London.

The study, published today in the British Journal of Psychiatry, found that antidepressants were prescribed more often and used more regularly in countries with higher levels of healthcare spending. In addition, beliefs that people with a mental illness are 'dangerous' were associated with higher use, whereas attitudes that they 'never recover' or 'have themselves to blame' were associated with lower and less regular use of antidepressants.

This research is the first to examine the reasons behind variation in the prescription practices of antidepressants across Europe.

The King's College London research team used data from the Eurobarometer 2010, a large survey of the general population in 27 European countries, to measure antidepressant prescription and regularity of use. They compared this data to the health expenditure of individual European countries and country-level attitudes towards mental health problems.

There was wide variation in antidepressant use across Europe, from 16 per cent of the general population in Portugal to only 3 per cent in Greece. In the UK, 9 per cent of the population had used antidepressants in the past 12 months.

It was previously known that there was a high level of variation, despite no evidence of difference in the prevalence of mental health disorders. For example, previous research had found that doctors in Iceland prescribed 6.4 times as many antidepressants per person as those in Estonia in 2010.

The new King's study also confirmed previous findings that women and middle-aged/older adults are less likely to take antidepressants.

Dr Sara Evans-Lacko, Lecturer in Health Services and Population Research at King's College London, said: 'Our research provides new insights into how social attitudes and government spending on healthcare are associated with antidepressant use.

'Antidepressant prescriptions are increasing at a rate of 20 per cent every year across Europe as a whole. Finding a balance between overprescription and underprescription of antidepressants is difficult. We need to address the stigma in countries with low antidepressant prescription to ensure that people who need treatment are able to get it. However, we also need to address the reasons behind the high prescription of antidepressants in some European countries.'

The study authors suggest that higher use of antidepressants in countries where people with mental illnesses are viewed as 'dangerous' may reflect a greater propensity towards help-seeking and more support for coercive treatment.

On the other hand, living in a country with stronger beliefs that people with mental illness 'have themselves to blame' or 'never recover' was associated with a lower likelihood of using antidepressants and lower regularity of use. According to the authors, this might be explained by the view of mental illness as a personality fault or incurable illness, which may reduce the likelihood of seeking out and using medical therapies.

Dr Evans-Lacko added: 'The perception that people with mental illness cannot recover or are blameworthy for their illness appears to be a strong barrier to antidepressant use in some countries. Countering these beliefs through public health campaigns and other interventions may contribute to more appropriate use of antidepressant medications.'


For further media information please contact Jack Stonebridge, Press Officer, Institute of Psychiatry, Psychology & Neuroscience, King's College London (+44) 020 7848 5377

About King's College London:

King's College London is one of the top 20 universities in the world (2014/15 QS World University Rankings) and among the oldest in England. King's has more than 26,500 students (of whom nearly 10,400 are graduate students) from some 150 countries worldwide, and nearly 6,900 staff. The university is in the second phase of a £1 billion redevelopment programme which is transforming its estate.

King's has an outstanding reputation for world-class teaching and cutting-edge research. In the 2014 Research Excellence Framework (REF) King's was ranked 6th nationally in the 'power' ranking, which takes into account both the quality and quantity of research activity, and 7th for quality according to Times Higher Education rankings. Eighty-four per cent of research at King's was deemed 'world-leading' or 'internationally excellent' (3* and 4*). The university is in the top seven UK universities for research earnings and has an overall annual income of more than £600 million.

King's has a particularly distinguished reputation in the humanities, law, the sciences (including a wide range of health areas such as psychiatry, medicine, nursing and dentistry) and social sciences including international affairs. It has played a major role in many of the advances that have shaped modern life, such as the discovery of the structure of DNA and research that led to the development of radio, television, mobile phones and radar.

King's College London and Guy's and St Thomas', King's College Hospital and South London and Maudsley NHS Foundation Trusts are part of King's Health Partners. King's Health Partners Academic Health Sciences Centre (AHSC) is a pioneering global collaboration between one of the world's leading research-led universities and three of London's most successful NHS Foundation Trusts, including leading teaching hospitals and comprehensive mental health services. For more information, visit:

King's fundraising campaign - World questions|King's answers - created to address some of the most pressing challenges facing humanity has reached its £500 million target 18 months ahead of schedule. The university is now aiming to build on this success and raise a further £100 million by the end of 2015, to fund vital research, deliver innovative new treatments and to support scholarships. The campaign's five priority areas are neuroscience and mental health, leadership and society, cancer, global power and children's health. More information about the campaign is available at

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.